DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Andrew drives the strategic direction of the team, builds and maintains long-term strategic partnerships with clients, and translates domain knowledge into substantial value for the department.

Andrew Merron, Ph.D leads the global oncology team of 25 analysts and directors and is responsible for creating and directing broad oncology strategy, developing long-term strategic partnerships with clients, and translating domain knowledge into actionable solutions.

Andrew has more than a decade of experience in commercial oncology analysis; his specific areas of expertise and interests include prostate cancer, hematological malignancies, real world evidence, clinical trial design and clinical development strategies. He has extensive experience in forecasting oncology and hematology-oncology drug markets as well as considerable experience in conducting primary research with physicians and payers across the major pharmaceutical markets. Previously, Andrew led and managed the Biosimilars Advisory Service at Decision Resources; the Biosimilars Advisory Service spans multiple therapy areas including oncology.